This investment expands Astellas’ capacity and capabilities for aseptic drug products, reinforces stable global production, and accelerates the development and commercialization of innovative antibody drugs and other new products. The Tralee facility is being built in line with Astellas’ ambitious sustainability targets, incorporating the highest national and international best practices in energy and environmental design. The project aims to cut water use by about half, reduce operational energy intensity by more than one-third, and produce zero waste to landfill compared with LEED® baseline. These measures, along with onsite renewable technology including solar PV panels and a biomass boiler, underpin Astellas’ efforts to mitigate climate change.
